Home Other Building Blocks IMD-0354

IMD-0354

CAS No.:
978-62-1
Catalog Number:
AG0036S1
Molecular Formula:
C15H8ClF6NO2
Molecular Weight:
383.6729
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$97
- +
5mg
≥98%
1 week
United States
$147
- +
10mg
≥98%
1 week
United States
$198
- +
50mg
99%
1 week
United States
$423
- +
Product Description
Catalog Number:
AG0036S1
Chemical Name:
IMD-0354
CAS Number:
978-62-1
Molecular Formula:
C15H8ClF6NO2
Molecular Weight:
383.6729
MDL Number:
MFCD00218820
IUPAC Name:
N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide
InChI:
InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)
InChI Key:
CHILCFMQWMQVAL-UHFFFAOYSA-N
SMILES:
Clc1ccc(c(c1)C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F)O
UNII:
76145IS906
Properties
Complexity:
462  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
383.015g/mol
Formal Charge:
0
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
383.674g/mol
Monoisotopic Mass:
383.015g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
49.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.2  
Literature
Title Journal
Central IKK2 Inhibition Ameliorates Air Pollution-Mediated Hepatic Glucose and Lipid Metabolism Dysfunction in Mice With Type II Diabetes. Toxicological sciences : an official journal of the Society of Toxicology 20180701
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Structure-activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling. Bioorganic & medicinal chemistry 20130101
Salicylanilide inhibitors of Toxoplasma gondii. Journal of medicinal chemistry 20121011
Activation of nuclear factor-κB pathway is responsible for tumor necrosis factor-α-induced up-regulation of endothelin B2 receptor expression in vascular smooth muscle cells in vitro. Toxicology letters 20120307
An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer science 20120101
Regulation of cytochrome P450 4F11 by nuclear transcription factor-κB. Drug metabolism and disposition: the biological fate of chemicals 20120101
A novel IKK inhibitor prevents progression of restenosis after arterial injury in mice. International heart journal 20120101
Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Molecular vision 20120101
IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice. World journal of gastroenterology 20111221
IκB kinase β inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20110101
Poly(I:C) reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cells. Toxicology and applied pharmacology 20110101
A novel NF-κB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Research in veterinary science 20101201
Copper activation of NF-kappaB signaling in HepG2 cells. Journal of molecular biology 20091113
Activation of host antiviral RNA-sensing factors necessary for herpes simplex virus type 1-activated transcription of host cell fucosyltransferase genes FUT3, FUT5, and FUT6 and subsequent expression of sLe(x) in virus-infected cells. Glycobiology 20090701
Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. International archives of allergy and immunology 20090101
NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiation research 20090101
Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis. Journal of gastroenterology 20090101
Lipid-soluble smoke particles upregulate vascular smooth muscle ETB receptors via activation of mitogen-activating protein kinases and NF-kappaB pathways. Toxicological sciences : an official journal of the Society of Toxicology 20081201
Mechanism of signal transduction in tumor necrosis factor-like weak inducer of apoptosis-induced matrix degradation by MMP-3 upregulation in disc tissues. Spine 20081101
Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. Journal of medical and dental sciences 20080301
Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Journal of molecular and cellular cardiology 20070801
Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice. The Journal of investigative dermatology 20070401
Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. American journal of physiology. Heart and circulatory physiology 20070101
Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. Modern rheumatology 20070101
A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. American journal of respiratory and critical care medicine 20060501
A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer research 20060101
A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 20050315
A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochemical and biophysical research communications 20041008
Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size. Cardiovascular research 20040701
Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovascular research 20040701
Properties